Investing in Novel Medical Technologies Panel
“Innovation in Medical Technologies - Devices, Diagnostics, and mHealth"
- Moderator: Tim Van Biesen, PhD, Partner, Head of Americas Healthcare Practice, Bain & Company
- Susan Hertzberg '97, President & Chief Executive Officer, Boston Heart Diagnostics
- Susan Morano '97, Vice President, New Business Development, Johnson & Johnson Medical Devices and Diagnostics
- Michael Singer, President and Chief Executive Officer, BrainScope
- Rafael Torres, Head of Healthcare, GE Ventures
- Examples of novel medical technologies to improve patient care and/or reduce healthcare costs.
- How are mobile health applications being used by physicians, patients, and health plans?
- What is the current regulatory and payer environment for the approval, adoption, and reimbursement of new medical products, including mHealth applications?
- What advances are being pursued in esoteric diagnostic testing to improve patient safety and efficacy?
- What type of business collaborations are we seeing between and among manufacturers, providers and payers?
- What is the primary focus of private investors (PE/VC) in this space?
Head of Americas Healthcare Practice
Bain & Company
Tim van Biesen leads Bain's Healthcare Practice in the Americas; he is based in the New York office. Tim was previously a senior scientist in neuroscience research at Abbott Laboratories. He has 13 years of consulting experience in the healthcare industry, and more than 10 years experience as a research scientist.
Tim’s areas of expertise span the full range of healthcare sub-sectors, including manufacturers, payers, providers and services. He has helped clients develop corporate growth strategy, R&D strategy, brand sales & marketing strategy, licensing and acquisitions, post merger integration and, manufacturing and supply chain strategy. In addition to his work with corporate clients, Tim supports the firm’s advisory work for private equity investors in the healthcare sector.
Dr. van Biesen has published more than 30 papers in peer-reviewed journals including Nature, Proceedings of the National Academy of Science, and The Journal of Biological Chemistry, and is an inventor on two patents covering four human genes. He is a Board member of the National Stroke Association.
He received his MBA from the Kellogg Graduate School of Management, Northwestern University and has a Ph.D. and B.Sc. in Molecular Microbiology from the University of Alberta. Tim conducted his post-doctoral fellowship at Duke University/Howard Hughes Medical Institute in the laboratory of Dr. Robert J. Lefkowitz, the 2012 Nobel Laureate in Chemistry.
President & CEO
Boston Heart Diagnostics
Susan joined Boston Heart Diagnostics in July, 2010 as President and Chief Executive Officer. Susan has held executive positions in both early-stage and established companies including Ipsogen Inc, a cancer molecular diagnostics firm, Quest Diagnostics, Abbott Diagnostics and Oxford Health Plans.
Her deep experience in diagnostics and payor contracting has given her a unique perspective on the market. At Quest, Ms. Hertzberg led several key functional areas over her time in the company. From health plan contracting to marketing, specialty sales, and purchasing and supply chain she innovated and transformed the organizations that she led and delivered exceptional top and bottom line results. At Oxford, Ms. Hertzberg, ran ancillary/laboratory contracting and was instrumental in pioneering a novel payment structure that is still widely used today. At Abbott, she headed up a then newly created global accounts management group that supported strategic customers around the world. She has successfully driven a change management and growth agenda under a variety of conditions and has anticipated shifting healthcare trends throughout her career and has used this to innovate along the way.
In 2013, she was named an Ernst and Young "Entrepreneur of the Year" for New England. Additionally, under her leadership, Boston Heart has received numerous accolades including the Forbes list of America’s 100 Most Promising Companies, The Deloitte Technology Fast 500 (# 1 in healthcare) and the Boston Globe’s “Best Places to Work” list.
Susan received a MBA from Columbia University and a BA from Clemson University. She serves on the Boston area Board of Directors of the American Heart Association and is a past director at TheraCare, Inc. a private healthcare, rehabilitation, developmental and educational service organization.
Vice President, New Business Development
Johnson & Johnson Medical Devices and Diagnostics
As Vice President of New Business Development and a member of the Medical Devices & Diagnostics Group Operating Committee, Susan has responsibility for strategic planning and licensing & acquisitions for the Medical Devices & Diagnostics Group.
Susan joined Johnson & Johnson in 1986 as a college recruit in the finance organization. During her tenure in the Corporation, she transitioned through a number of positions with increasing responsibility through six operating companies, primarily within finance and new business development. Susan has been involved in a number of significant transactions within MD&D.
Ms. Morano received her BS in accounting from Villanova University and an MBA from Columbia University.
President & CEO
Michael Singer has over 25 years of executive leadership, healthcare and financial experience. During his six year tenure at BrainScope, he has been instrumental in guiding the company through development and clinical validation of a product to aid in the assessment of Traumatic Brain Injury, while securing Venture Capital investment and non-dilutive research funding through military contracts. Before he joined BrainScope, he was President of Revolution Health Investments, where he managed its sale to Everyday Health. He was previously the Chief Financial Officer, Executive Vice President of Corporate Development and a Board member for Data Critical, a Seattle-based venture-backed wireless healthcare informatics and medical device company. At Data Critical he was responsible for facilitating the company’s IPO, overseeing all financial functions, managing acquisitions and partnerships and eventually led the sale of Data Critical to GE. He has also worked as an executive at Microsoft Corporation responsible for developing small business and healthcare strategies, and for a decade as a healthcare investment banker and M&A generalist for Wolfensohn & Co., Montgomery Securities and Alex. Brown in New York and San Francisco. He started his career at Union Bank of Switzerland in Zurich. He holds a Ph.D. from the London School of Economics.
Head of Healthcare
Rafael Torres leads the VC team for healthcare investments and directs portfolio strategy. Under Rafael’s leadership, GE Ventures has invested in multiple successful healthcare businesses including Nanostring (NASDAQ: NSTG) and Veracyte (NASDAQ: VCTY). Previously, Rafael was the global healthcare leader for GE Equity, GE’s private equity platform, where he built a practice with over 30 investments including ParadigmHealth (Alere), Navinet (Horizon Blue Cross) and Euromedic (BAML Capital). Rafael has had a variety of board roles including CardioDx, InSightec, Navinet, ParadigmHealth and LipoScience. In previous roles at GE, Rafael served as an operating executive in the integration of GE’s largest healthcare acquisition, Amersham and in the M&A team of GE Healthcare. He has been a judge in the Assembling Tools to Fight Cancer challenge by GE and featured in leading healthcare publications including The Gray Sheet, Medical Device Daily and MedCity News. Before joining GE, Rafael held various positions at The Boston Consulting Group, AT Investments and Citibank. Rafael received his MBA from Harvard Business School and BA in Economics from Universidad del Pacifico.